# Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct04921527/  
OnCo record `nct04921527` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Chiauranib in ovarian cancer, now recruiting.

## Summary

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer is a phase 3 interventional study registered as NCT04921527, led by Chipscreen Biosciences, and recruiting on the registry. Official title: A Multi-centre, Double-blind, Randomised Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer. Planned enrolment is 454 participants (estimated). The study started in 2021-12-20 and primary completion is expected in 2024-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: CHIPRO
- Tags: ctgov-ingest
- Registry id: NCT04921527
- Phase: 3
- Setting: A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
- Sponsor: Chipscreen Biosciences
- Enrolled: 454

## Sources

- ClinicalTrials.gov NCT04921527: https://clinicaltrials.gov/study/NCT04921527

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [Chiauranib](https://onco.cc/drugs/chiauranib/)
- companies: [Chipscreen Biosciences](https://onco.cc/companies/chipscreen/)

---
JSON: https://onco.cc/api/v1/entities/nct04921527.json